BullFrog AI Enters Feasibility Agreement With Pharma for MDD Targets

What Happened
BullFrog AI Holdings, Inc. announced on March 30, 2026 (agreement dated March 27, 2026) that it entered a one‑year Feasibility Agreement with a global pharmaceutical company to apply its bfLEAP® AI/ML platform to discover and prioritize drug target candidates for major depressive disorder (MDD). The Company is eligible for predetermined milestone payments tied to deliverables, and the Client has an option to obtain exclusive rights to a selected final target for R&D use for three years. A press release announcing the agreement was issued March 30, 2026.

Key Details

• Agreement date: March 27, 2026; press release filed March 30, 2026.
• Term: one year from execution.
• Payment: Company eligible for pre‑determined milestone payments upon delivery of specified deliverables (financial terms not disclosed).
• Client rights: option to receive exclusive use of a selected “final target” for three years for R&D.
• Termination: Client may terminate without cause with 30 days’ notice; either party may terminate for uncured material breach after 30 days’ notice.
• Scope: bfLEAP® will deliver prioritized target candidates, causal gene networks (with near‑neighbors unblinded), and target dossiers for advancement‑ready drug candidates for MDD.
• Certain portions of the Feasibility Agreement are redacted in the public filing.

Why It Matters
This agreement represents a commercial engagement for BullFrog AI’s bfLEAP platform with a global pharmaceutical partner, potentially generating milestone revenue and creating a pathway to a multi‑year research relationship if the client exercises the exclusive‑use option. However, the filing does not disclose payment amounts or the likelihood the client will exercise the option, so investors should view this as evidence of commercial traction rather than a guaranteed revenue stream.